Advair HFA 230/21 (fluticasone propionate 230 mcg and salmeterol 21 mcg*) Inhalation Aerosol
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) -- March 2008
|The detailed view includes drug products with safety labeling changes to the BOXED WARNING, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS, or PATIENT PACKAGE INSERT/MEDICATION GUIDE sections. Deletions or editorial revisions made to these sections are not included in this summary.|
|Sections Modified||Summary of Changes to Contraindications and Warnings|
Potential drug interaction with CYP 3A4 inhibitors
Both fluticasone propionate and salmeterol are substrates of CYP 3A4.